Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer

Ruocong Zhao, Yuanbin Cui, Yongfang Zheng, Shanglin Li, Jiang Lv, Qiting Wu, Youguo Long, Suna Wang, Yao Yao, Wei Wei, Jie Yang, Bin-Chao Wang, Zhenfeng Zhang, Hui Zeng, Yangqiu Li, Peng LiFrontiers in Immunology 2021 · DOI

TL;DR

This study tackles the challenge of CAR-T cell efficacy in solid tumors by addressing the physical barrier posed by hyaluronic acid (HA) in the tumor microenvironment. By engineering CAR-T cells to co-express a secreted hyaluronidase (sPH20-IgG2), researchers significantly enhanced their ability to infiltrate tumors and suppress gastric cancer growth in preclinical models.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematological malignancies, but its success in solid tumors has been limited. A major hurdle is the tumor microenvironment (TME), which often contains immunosuppressive elements and physical barriers that impede CAR-T cell infiltration and function. One such barrier is hyaluronic acid (HA), a component of the extracellular matrix (ECM) that can accumulate in solid tumors. High levels of HA can increase interstitial fluid pressure and create a physical impediment, hindering the ability of CAR-T cells to reach and attack cancer cells. This paper investigates whether targeting HA can improve the efficacy of CAR-T cell therapy for gastric cancer.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They analyzed gene expression data to correlate the expression of hyaluronic acid synthases (HAS), enzymes responsible for HA production, with patient survival in various solid tumors, including gastric cancer.
  • Vector Engineering: They designed lentiviral vectors to express a secreted form of human hyaluronidase PH20 (sPH20-IgG2). This involved replacing the native PH20 signal peptide with a tissue plasminogen activator (tPA) signal peptide to ensure secretion, and fusing it with an IgG2 Fc fragment for potential stabilization.
  • Cell Culture and Transduction: They transduced primary human T cells with lentiviruses to generate CAR-T cells. Specifically, they created anti-mesothelin (MSLN) CAR-T cells and co-expressed sPH20-IgG2 with these CAR-T cells (termed anti-MSLN-sP CAR-T cells).
  • In Vitro Assays:
    • Hyaluronidase Activity Assay: They measured the ability of engineered T cells to degrade HA.
  • Transwell Assays: These were used to assess T cell migration through HA-containing matrices and to evaluate the killing efficacy of CAR-T cells against gastric cancer cells in the presence of HA.
  • Cytokine Release Assays: They measured the secretion of key cytokines (IFN-γ, Granzyme B) by CAR-T cells to assess their effector function.
  • In Vivo Xenograft Models: They established gastric cancer xenograft models in immunodeficient mice (NSI mice) using human gastric cancer cell lines (BGC823 and MKN28). These mice were then treated with Mock-T cells, anti-MSLN CAR-T cells, or anti-MSLN-sP CAR-T cells.
  • Tumor Growth Monitoring and Analysis: Tumor volumes and weights were measured over time. Immunohistochemistry (IHC) was used to assess T cell infiltration into tumors.

Datasets

  • Gene Expression Data: The study utilized the gene expression profiling interactive analysis (GEPIA) database to analyze the correlation between HAS expression and patient survival in various solid tumors.
  • Gastric Cancer Cell Lines: BGC823, KATOIII, MKN28, and MKN45 cell lines were used for in vitro experiments. Luciferase/GFP-expressing versions (BGC823-GL and KATOIII-GL) were generated for tumor killing assays.
  • Animal Models: NSI mice were used to establish subcutaneous xenograft models of gastric cancer.

Key Insights and Ideas

  • HA as a Barrier: The study strongly implicates HA as a significant impediment to CAR-T cell infiltration and anti-tumor activity in solid tumors, particularly gastric cancer. The negative correlation between HAS expression and patient survival underscores the clinical relevance of HA accumulation.
  • PH20 as a Solution: Engineering CAR-T cells to secrete hyaluronidase PH20 (sPH20-IgG2) effectively degrades HA, thereby breaking down this physical barrier.
  • Targeted Degradation, Not Global Disruption: The sPH20-IgG2 modification enhanced CAR-T cell transmigration and infiltration without negatively impacting their intrinsic cytotoxicity or cytokine secretion capabilities. This suggests a precise mechanism of action that augments, rather than broadly alters, CAR-T cell function.
  • Translational Potential: The successful demonstration of enhanced anti-tumor activity in both in vitro and in vivo models highlights the potential of this strategy for improving CAR-T cell therapy in solid tumors.

Key Results

  • Survival Correlation: High expression of HAS family members, particularly HAS2, was negatively correlated with patient survival in various solid tumors, including gastric cancer.
  • HA Impedes CAR-T Cells in vitro: HA significantly reduced the killing activity of anti-MSLN CAR-T cells against gastric cancer cell lines and impaired their migration through HA-containing matrices.
  • sPH20-IgG2 Enhances Migration: Jurkat cells and primary T cells engineered to express sPH20-IgG2 showed significantly enhanced hyaluronidase activity and improved transmigration through HA matrices.
  • Improved in vivo Efficacy: In gastric cancer xenograft models, anti-MSLN-sP CAR-T cells demonstrated superior tumor regression compared to conventional anti-MSLN CAR-T cells.
  • Increased T Cell Infiltration: Immunohistochemical analysis revealed significantly higher T cell infiltration in tumors treated with anti-MSLN-sP CAR-T cells compared to anti-MSLN CAR-T cells.
  • Reduced Tumor Burden: Mice treated with anti-MSLN-sP CAR-T cells exhibited smaller tumor volumes and weights.

Limitations and Future Work

  • Co-expression Efficiency: The authors acknowledge that the co-expression efficiency of sPH20-IgG2 with MSLN CAR in primary T cells was limited. They addressed this by flow-sorting GFP+ CAR MSLN+ double-positive T cells for further validation.
  • Animal Models: The study utilized immunodeficient mice, which do not fully recapitulate the complex immune interactions present in human tumors. The authors suggest that testing these strategies in more suitable humanized animal models would be beneficial.
  • Generalizability: While the study focused on gastric cancer, the findings have broader implications for other solid tumors where HA accumulation is a known issue. Future work could explore the efficacy of this approach in a wider range of solid tumor types.
  • Clinical Translation: The study highlights the substantial significance of this strategy and suggests it should be tested in further research models and ultimately in clinical trials.

Summary updated

Abstract

T cell infiltration into tumors is essential for successful immunotherapy against solid tumors. Herein, we found that the expression of hyaluronic acid synthases (HAS) was negatively correlated with patient survival in multiple types of solid tumors including gastric cancer. HA impeded <i>in vitro</i> anti-tumor activities of anti-mesothelin (MSLN) chimeric antigen receptor T cells (CAR-T cells) against gastric cancer cells by restricting CAR-T cell mobility <i>in vitro</i>. We then constructed a secreted form of the human hyaluronidase PH20 (termed sPH20-IgG2) by replacing the PH20 signal peptide with a tPA signal peptide and attached with IgG2 Fc fragments. We found that overexpression of sPH20-IgG2 promoted CAR-T cell transmigration through an HA-containing matrix but did not affect the cytotoxicity or cytokine secretion of the CAR-T cells. In BGC823 and MKN28 gastric cancer cell xenografts, sPH20-IgG2 promoted anti-mesothelin CAR-T cell infiltration into tumors. Furthermore, mice infused with sPH20-IgG2 overexpressing anti-MSLN CAR-T cells had smaller tumors than mice injected with anti-MSLN CAR-T cells. Thus, we demonstrated that sPH20-IgG2 can enhance the antitumor activity of CAR-T cells against solid tumors by promoting CAR-T cell infiltration.
BibTeX
@inproceedings{zhao2021human,
  author = {Ruocong Zhao and Yuanbin Cui and Yongfang Zheng and Shanglin Li and Jiang Lv and Qiting Wu and Youguo Long and Suna Wang and Yao Yao and Wei Wei and Jie Yang and Bin-Chao Wang and Zhenfeng Zhang and Hui Zeng and Yangqiu Li and Peng Li},
  title = {{Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.660488},
}
Figure